Patents by Inventor Bernd Puellmann
Bernd Puellmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11981661Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein B, C, L, X, Y, RL and R3 to R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: GrantFiled: September 2, 2021Date of Patent: May 14, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Uwe Grether, Benoit Hornsperger, Carsten Kroll, Bernd Kuhn, Rainer E. Martin, Fionn O'Hara, Bernd Puellmann, Hans Richter, Martin Ritter
-
Patent number: 11814375Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: GrantFiled: September 10, 2020Date of Patent: November 14, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Luca Gobbi, Uwe Grether, Katrin Groebke Zbinden, Benoit Hornsperger, Carsten Kroll, Bernd Kuhn, Rainer E. Martin, Fionn O'Hara, Bernd Puellmann, Hans Richter, Martin Ritter
-
Publication number: 20230257354Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R9 and p are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.Type: ApplicationFiled: March 6, 2023Publication date: August 17, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Zhanling CHENG, Christian LERNER, Yongqiang LIU, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Jianhua WANG, Min WANG, Yongguang WANG, Song YANG, Chengang ZHOU
-
Publication number: 20230203043Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), or pharmaceutically acceptable salts thereof, wherein X and R3 to R9 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.Type: ApplicationFiled: October 28, 2022Publication date: June 29, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Jean-Baptiste BLANC, Christian LERNER, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Sébastien SCHMITT, Theodor STOLL, Song YANG, Chengang ZHOU
-
Publication number: 20230017532Abstract: Provided are novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.Type: ApplicationFiled: June 16, 2021Publication date: January 19, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Zhanling CHENG, Nawaz KHAN, Christian KRAMER, Christian LERNER, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Sebastien SCHMITT, Theodor STOLL, Jianhua WANG, Song YANG
-
Publication number: 20230012368Abstract: Provided are novel imidazopyrazine derivatives having the general formula (I), wherein R1 to R11 are as described herein and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.Type: ApplicationFiled: June 16, 2021Publication date: January 12, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Jean-Baptiste BLANC, Zhanling CHENG, Xingchun HAN, Nawaz KHAN, Christian KRAMER, Holger KUEHNE, Christian LERNER, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Sebastien SCHMITT, Theodor STOLL, Jianhua WANG, Yongguang WANG, Song YANG
-
Publication number: 20220396565Abstract: Provided are novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R4, m, n, and p are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.Type: ApplicationFiled: July 20, 2022Publication date: December 15, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Zhanling CHENG, Xingchun HAN, Christian KRAMER, Christian LERNER, Yongqiang LIU, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Jianhua WANG, Lisha WANG, Min WANG, Yongguang WANG, Song YANG, Chengang ZHOU
-
Patent number: 11390604Abstract: The disclosure provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X1, RA and R3 to R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.Type: GrantFiled: March 6, 2020Date of Patent: July 19, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Jean-Baptiste Blanc, Christian Kramer, Christian Lerner, Matthias Nettekoven, Philippe Pflieger, Bernd Puellmann, Thomas Ryckmans, Sébastien Schmitt, Min Wang, Song Yang, Chengang Zhou
-
Publication number: 20220106328Abstract: The invention provides new heterocyclic compounds having the general formulae (Ia) and (Ib) wherein A, B, and L are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: December 16, 2021Publication date: April 7, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
-
Publication number: 20220098176Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein B, C, L, X, Y, RL and R3 to R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 2, 2021Publication date: March 31, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O'HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
-
Publication number: 20210094943Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and RI to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 10, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
-
Publication number: 20210094972Abstract: The invention provides new heterocyclic compounds having the general formulae (Ia) and (Ib) wherein A, B, and L are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 22, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
-
Publication number: 20200290998Abstract: The disclosure provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X1, RA and R3 to R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.Type: ApplicationFiled: March 6, 2020Publication date: September 17, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Jean-Baptiste Blanc, Christian Kramer, Christian Lerner, Matthias Nettekoven, Philippe Pflieger, Bernd Puellmann, Thomas Ryckmans, Sébastien Schmitt, Min Wang, Song Yang, Chengang Zhou
-
Publication number: 20160083357Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: December 4, 2015Publication date: March 24, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
-
Patent number: 9090615Abstract: The invention relates to a compound of formula (I) wherein A1, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: GrantFiled: December 22, 2014Date of Patent: July 28, 2015Assignee: HOFFMANN-LA ROCHE INC.Inventors: Atsushi Kimbara, Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Mark Rogers-Evans, Tanja Schulz-Gasch
-
Publication number: 20150111886Abstract: The invention relates to a compound of formula (I) wherein A1, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: December 22, 2014Publication date: April 23, 2015Applicant: Hoffmann-La Roche Inc.Inventors: Atsushi Kimbara, Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Mark Rogers-Evans, Tanja Schulz-Gasch
-
Patent number: 7691863Abstract: The present invention relates to compounds of the formula wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB2 receptors.Type: GrantFiled: September 24, 2007Date of Patent: April 6, 2010Assignee: Hoffman-La Roche Inc.Inventors: Michel Dietz, Sabine Gruener, Paul Hebeisen, Sylvie C. Meyer Reigner, Matthias Nettekoven, Bernd Puellmann, Stephan Roever, Christoph Ullmer
-
Publication number: 20080085905Abstract: The present invention relates to compounds of the formula wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB2 receptors.Type: ApplicationFiled: September 24, 2007Publication date: April 10, 2008Inventors: Michel Dietz, Sabine Gruener, Paul Hebeisen, Sylvie Meyer Reigner, Matthias Nettekoven, Bernd Puellmann, Stephan Roever, Christoph Ullmer
-
Patent number: 6514989Abstract: The invention is a compound of formula or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined in the specification. A compound of formula I has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor.Type: GrantFiled: May 29, 2002Date of Patent: February 4, 2003Assignee: Hoffmann-La Roche Inc.Inventors: Matthias Heinrich Nettekoven, Bernd Puellmann